meability of capillary walls, preventing edema, inhibiting platelet aggregation, and improving microcirculation (20) (21) (22) (23) , in flights lasting 7-12 hours in subjects at mild-to-moderate thrombotic risk.
PATIENTS AND METHODS
Risk criteria for DVT are those previously indicated in LONFLIT studies 1, 2, and 3 (14) (15) (16) (17) (18) (19) (20) . Subjects with a body-mass index (BMI) greater than 28, taller than 190 cm, and heavier than 90 kg were excluded.
Ultrasound Scanning Protocol (before/after flights)
Sonosite scanners with a 7.5-to 13-MHz, high-resolution, linear probe (Sonosite, Bothell, WA, USA) were used to study the venous system by compression of the major veins (femorals, popliteals, and tibials) (20, 21) .
Exclusion criteria were any clinical disease requiring treatment, severe bone/joint problems or limited mobility, uncontrolled diabetes, severe hypertension, obesity, recent thrombosis (less than 6 months), or the presence of thrombi at the pre-flight examination.
Scanning Plan
Scanning was performed within 12 hours before the flight and repeated after the flights (within 12 hours) to exclude venous thrombosis. A thrombotic event was detected when a noncompressible vein clot was observed by ultrasound (both in the deep system and in the superficial veins). The presence of inflammation of a superficial vein, without thrombosis, was defined as phlebitis (24) (25) (26) (27) .
An Independent Study
The study was not sponsored by the companies producing the materials quoted in this article. The compound was supplied-without conditions-by Horphag Research Management SA, Geneva, Switzerland.
Exercise Plan
An exercise plan was presented to all included subjects in an educational video explaining venous thrombosis and its prevention. It consisted of mild exercise (standing and moving legs for 5 to 10 minutes every hour), avoiding baggage between seats, and drinking regularly (100 to 150 mL of water every hour).
Pycnogenol ® Administration
Subjects received two capsules between 2 and 3 hours before flights with 250 mL of water and two capsules 6 hours later with 250 mL of water and one capsule the next day. Placebo and verum were packed in plastic bottles containing 10 capsules with instructions concerning how and when to take the capsules. Placebo capsules were administered accordingly to the control group with the same amount of fluid. The Pycnogenol ® capsules included 100 mg of Pycnogenol ® (20) (21) (22) (23) . Pycnogenol ® has been demonstrated to reverse symptoms of venous insufficiency, such as swelling, itching, and cramps. Pycnogenol ® only rarely may produce minor side effects (20) (21) (22) (23) .
The study hypothesis was that Pycnogenol ® reduces edema and signs and symptoms linked to swelling. This compound also controls the enhanced platelet aggregation in situations of immobility, particularly in moderate-to high-risk individuals. Pycnogenol ® is an aqueous, dry extract from the bark of the French maritime pine. It is a natural blend of constant proportions of bioflavonoids including catechin, epicatechin, taxifolin, oligomeric proanthocyanidins, and phenolic acids as ferulic acid and caffeic acid. Clinical studies in thousands of patients have shown, very rarely, only mild, temporary side effects (20) (21) (22) (23) .
Evaluation of Edema
The assessment of edema was performed by an analogue scale (range, 0-12) as shown in Fig.  1 , considering a composite edema score. The arbitrary scale includes both objective and subjective elements. The first observation was the global value of edema measured by an analogue scale line as observed by the observer performing measurements and evaluation. The edema level perceived by the subject under investigation, the level of edema visually observed by the observer, and the presence of signs/symptoms were also included. The rate of ankle swelling was measured by strain-gauge (RAS).
Technique Description
The patient is evaluated in the supine position and a strain gauge (Hokanson, USA) is applied at the smallest circumference of the ankle. After basic recording and volume calibration, the patient is asked to stand, holding onto a frame. The variations in volume are measured in 10 minutes. Usually, the first 3 to 4 minutes are associated with a volume increase due to venous filling. The following period of 3 to 4 minutes can be attributed to venous stretching. The final period (1 to 2 minutes) is due to filtration of fluid into the extravascular compartment. Therefore, the tangent to the curve/line relative to the 10th minute defines the filtration and capillary leakage (rate of ankle swelling) (24) (25) (26) (27) (28) . The method was applied only in patients willing to have the test (i.e., those with connections were excluded) because it required some time after the end of the flight. Therefore it was performed in a number of unselected subjects (the aim was to have a representative sample of at least one out of three of the evaluation subjects studied with RAS) (28) (29) (30) (31) .
The variation in ankle circumference was measured with a tape at the smallest circumference at the ankle; as a value of 100% was the combined (left+right/2) circumference at inclusion, before the flight, the percent variations were recorded just after the flight.
Tolerability and compliance were evaluated by direct questioning. The problems concerning tolerability were structured in four items: gastrointestinal problems, skin alterations, signs of allergic reaction, and any other manifestation. The problems were discussed informally with the subjects collecting unstructured, spontaneous reports and observations. 
PREVENTION OF EDEMA IN LONG FLIGHTS WITH PYCNOGENOL

Variations in edema score before and after long flights (1=controls; 2=Pycnogenol ® )
Statistical analysis was conducted using nonparametric tests and the analysis of variance considering subjects completing the protocol. Table 1 shows the data concerning the groups of subjects evaluated for edema. The study included 211 subjects; 169 completed (age 45; SD 12) the study (88 in the control group and 81 in the Pycnogenol ® group). There were no important differences between the two groups as they were comparable for age, gender, weight, BMI, and pattern distribution.
RESULTS
The edema score, the RAS, and the circumference at inclusion were also comparable in the two groups ( Table 2 , Figs. 1 and 2 ). After the flight in those treated with Pycnogenol ® , the edema score was increased only 17.9% (vs. an increase of 58.3% in the control group) (p<0.05).
The RAS, evaluated in 22 subjects in the Pycnogenol ® group (age 44.5; SD 8) and in 23 in the control group (age 45; SD 9) was increased on average 91% in the control group and only 36% in the Pycnogenol ® group (p<0.05). Also the variation in circumference at the ankle was only 6% in the Pycnogenol ® group vs. 11% in the control group (p<0.05).
These results indicate a positive effect of Pycnogenol ® on edema during long flights when we consider both subjective and objective data. No side effects were reported.
CONCLUSIONS
Travel-related edema, swelling, and DVT are preventable conditions (1) (2) (3) (4) (5) (6) (7) (8) (9) . Most travel-related problems are neglected being mostly asymptomatic (22) (23) (24) (25) . In long flights (> 12-18 hours) between 4% and 10% of passengers may be affected by DVT according to risk categories and all subjects show some level of edema. New studies are still needed to evaluate the incidence and epidemiology of travel and flight-related problems such as edema and DVT, and the costs and benefits of different methods of prophylaxis (31) (32) (33) (34) (35) . Edema, easy to observe at the lower limbs, can be also present at several other levels particularly in subjects prone to edema such as those under antihypertensive treatment (34) (35) (36) . The effects of edema could be more important than expected as retinal and brain edema have been episodically described and can be associated with vision problems and, after the flights, to sleep and behavioral pattern alterations, which may be associated or confused with jet-lag symptoms. Actually, in our experience, in several subjects and patients with high levels of edema, after long flights, the presence of subclinical edema has been detected with cerebral magnetic resonance imaging or computed tomography scans in some cases associated with severe alterations after flights (speech alterations and sleep disorders). However these observations require a more focused study and specific attention, particularly to older subjects prone to edema. In long-haul flight, the real target is to prevent DVT and PE (37) . However, most patients complain of swelling. An exercise plan is helpful but often it is not easy to perform or to perform sufficiently. It is reasonable to assume that controlling edema could be an important step to decrease the associated incidence of DVT. Exercise during flights, controlled fluid intake, diet suggestions, less baggage on board to keep free leg space and larger empty spaces on planes may help, as well as suggestions from physicians not to travel in conditions of increased risk. Anti-edema and anti-thrombotic prophylaxis with Pycnogenol ® may offer a very important option for preventing problems during flights because it combines the effect of edema reduction and inhibition of platelet aggregation, which may lead in some subjects to fewer thrombotic events (38) .
New observations (39, 40) define better that the risk of edema and DVT is not minimal during travel, even during long bus travels, and that prevention of edema is very important.
The observations resulting from this study indicate that flight-edema prevention with Pycnogenol ® is effective and well tolerated. 
Groups (1=controls; 2=Pycnogenol ® )
